← Back to Stock Screener← Stock Screener

ZYBERNO

Stock Report

Updated Jun 5, 2026

DAY ONE BIOPHARMACEUTICALS, INC. (DAWN)

Healthcare • NASDAQ

$21.53

Professional Investment Analysis

ZYBERNO SCORE →

Is it a great business? Is it getting better?

30.0/100

WEAK BUSINESS

DAY ONE BIOPHARMACEUTICALS, INC. (DAWN) scores 30/100 — weak fundamentals with mixed indicators requiring careful analysis before acting.

📊 How is the Zyberno Score calculated? +

The Zyberno Score answers one question: "Is this a quality business worth owning?" It's a 0-100 investment grade that evaluates business fundamentals across four critical dimensions, based on principles from Warren Buffett, Benjamin Graham, Peter Lynch, and Charlie Munger.

The 4 Core Categories (25 points each):

1. PROFITABILITY (25 pts)

Metrics: ROE, ROIC, Net Margin, Operating Margin
Thresholds: ROE >20% excellent • ROIC >20% excellent • Net Margin >20% excellent • Operating Margin >25% excellent

2. FINANCIAL STRENGTH (25 pts)

Metrics: Debt-to-Equity, Current Ratio, Interest Coverage, Altman Z-Score
Thresholds: D/E <0.3 excellent • Current Ratio >2.5 excellent • Interest Coverage >10x excellent • Altman Z >3.0 safe

3. CASH FLOW QUALITY (25 pts)

Metrics: Free Cash Flow, OCF vs Net Income, FCF Margin
Thresholds: Positive & growing FCF excellent • OCF/NI >1.2x excellent (cash earnings exceed accounting)

4. GROWTH & CONSISTENCY (25 pts)

Metrics: Revenue Growth, Net Income Growth, FCF Growth, Piotroski F-Score
Thresholds: Growth via log-linear regression • Piotroski 8-9 excellent, 6-7 good

Score Interpretation:

75-100

GREAT BUSINESS

65-74

GOOD BUSINESS

50-64

AVERAGE BUSINESS

30-49

WEAK BUSINESS

0-29

POOR BUSINESS

→ View full DAWN quality analysis & detailed breakdown

VALUATION SIGNAL

N/A (Requires more data)

Requires fair value calculation and current price data

💰 How is Margin of Safety calculated? +

Margin of Safety measures how much discount or premium you're paying relative to a stock's intrinsic value. It's Benjamin Graham's core principle: the larger the margin, the lower your downside risk.

Formula: (Intrinsic Value − Current Price) ÷ Intrinsic Value × 100%

How We Calculate Intrinsic Value (DCF Method):

Step 1: Calculate current Owner Earnings (OCF − Maintenance CapEx)

Step 2: Calculate company-specific growth rate using log-linear regression on 16 quarters of Owner Earnings

Step 3: Project 10 years forward using the calculated growth rate

Step 4: Discount each year's cash flow to present value using 10% discount rate

Step 5: Calculate terminal value using 3% perpetual growth rate

Step 6: Sum all discounted cash flows = Intrinsic Value

What The Percentages Mean:

+50% or more

EXCELLENT — Very undervalued

+25% to +50%

GOOD — Attractive discount

0% to +25%

FAIR — Reasonable value

0% to -25%

CAUTION — Slight premium

-25% or worse

POOR — Overvalued

"Price is what you pay, value is what you get." — Warren Buffett

→ View full DAWN valuation analysis · → View full DAWN Brina Gap analysis

📈 How is Brina Gap calculated? +

Brina Gap measures the difference between the growth a business can fundamentally sustain and the growth the market is already pricing in.

Formula: Fundamental Growth Rate − Market-Implied Growth Rate

The Two Components:

Fundamental Growth Rate = ROIC × Reinvestment Rate

What the business can sustainably grow at based on how much it reinvests and what return it earns on that capital. Grounded in historical financials.

Market-Implied Growth Rate = Reverse DCF

The growth rate the current Enterprise Value implicitly assumes. Calculated by back-solving a 10-year DCF model (10% WACC, 3% terminal growth) until the present value of projected cash flows equals EV.

What The Gap Means:

Gap > +5% Market Underestimates — potential upside

+2% to +5% Slight Underestimate

-2% to +2% Fairly Priced — market consensus matches fundamentals

-5% to -2% Slight Overestimate

Gap < -5% Market Overestimates — price embeds optimism fundamentals don't support

A positive gap (market underestimates) combined with a positive Margin of Safety is the strongest combined signal — the business is both cheap historically and forward economics are stronger than the price suggests.

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-23,427.9%)

Debt-to-Equity (Solvency Risk):EXCELLENT (0.01x)

Operating Margin (Operational Efficiency):CRITICAL (-80.8%)

Return on Capital (Capital Efficiency):CRITICAL (-31.8%)

📊 Valuation Trilogy

Three interconnected metrics for complete valuation analysis

Click any metric for full methodology and detailed analysis

Zyberno's Verdict

DAY ONE BIOPHARMACEUTICALS, INC. (DAWN) stock report — Zyberno Score 30/100 (WEAK BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, DAWN generated -$104.08M in Owner Earnings. Capital was deployed as follows: $320.00K invested in capital expenditures. Reinvestment rate: 2.9%.

DIVISION I: EXECUTIVE SUMMARY

A. Market Valuation

Market Price & Capitalization (2)

Current Price:21.53

Market Cap:$2.22B

Valuation Multiples (3)

P/B Ratio:5.04x

P/S Ratio:14.05x

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$2.08B

B. Profitability Assessment

Return Metrics (5)

ROE:

-23,427.9%

📊 Click to view full DAWN ROE analysis →

ROA:-20,688.6%

Roic:

-31.8%

📊 Click to view full DAWN ROIC analysis →

Reinvestment Rate:2.9%

Fundamental Growth Rate (g):-0.9%

Margin Analysis (3)

Operating Margin Ttm:-80.8%

Net Margin Ttm:-67,847.2%

Ebitda Margin:-78.8%

TTM Performance (2)

Operating Margin Ttm:-80.8%

Net Margin Ttm:-67,847.2%

Yield Metrics (2)

Earnings Yield:-$4.83

Dividend Yield:0.0%

C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

Earnings Surprise (SUE):

+0.00

📊 Click to view full DAWN Earnings Surprise analysis →

EPS Surprise vs Expected:0.8%

Latest Earnings Filed:2026-02-24

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-34.3%

D. Financial Stability

Liquidity Ratios (3)

Current Ratio:8.02x

Quick Ratio:7.91x

Cash Ratio:3.26x

Leverage Analysis (3)

Debt To Equity Ttm:0.01x

Debt-to-Equity Ratio:0.01x

Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:424,577,000.00

Cash And Cash Equivalents:197,078,000.00

Long Term Debt:$2.62M

Net Debt:-$139.84M

DIVISION II: FINANCIAL STATEMENTS ANALYSIS

A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $158.18M

Linear Growth: -34.3%

📊 Click to view full DAWN Revenue analysis & methodology →

Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$127.75M

Bottom Line Performance (3)

-$107.32B

Income Before Tax:$0.00

Ebitda Ttm:-124,640,000.00

Operating Expenses (5)

Operating Expenses:285,932,000.00

R And D Expense:148,135,000.00

Sga Expense:120,587,000.00

Income Tax Expense:-$1.98M

Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:275.8%

Sga To Revenue Percentage:224.5%

Ebitda Margin:-78.8%

B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$507.83M

Current Assets:$485.10M

Ppe Net:2,136,000.00

Goodwill:0.00

Intangible Assets:$18.02M

Liability Structure (4)

Total Liabilities:66,665,000.00

Current Liabilities:60,522,000.00

Long Term Debt:$2.62M

Short Term Debt:$54.62M

Equity & Capital (3)

Equity:$441.16M

Retained Earnings:-$661.40M

Common Stock:500,000,000.00

Working Capital Items (3)

Accounts Receivable:26,735,000.00

Inventory:6,326,000.00

Accounts Payable:54,615,000.00

Special Items (2)

Contract Liabilities:2,000,000.00

Stock Based Compensation:11,068,000.00

C. Cash Flow Analysis

Operating Activities (2)

-$103.76M-$104.08M

Investment Activities (2)

Investing Cash Flow:$167.48M

Capital Expenditures Ttm:320,000.00

Financing Activities (3)

Financing Cash Flow:$471.00K

Dividends Paid Ttm:0.00

Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00

Long Term Debt Issuance:$0.00

Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:3,110,000.00

DIVISION III: OPERATIONAL METRICS

A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.04

-$1.04

Earnings Per Share Ttm:-$1.04K

Revenue & Cash Per Share (2)

Sales Per Share Ttm:1.53

Operating Cash Flow Per Share:-$1.01

Book Value & Capital (2)

Book Value Per Share:$4.27

Cash Per Share:1.91

Dividend Policy (1)

Dividend Payout Ratio:-999.00x

B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.30x

Working Capital Turnover Ttm:0.37x

Receivables Management (2)

Receivables Turnover Ttm:5.92x

Days Sales Outstanding Ttm:61.69

Inventory Management (2)

Inventory Turnover Ttm:25.01x

Days Inventory Outstanding Ttm:14.60

Payables & Cash Cycle (2)

Days Payable Outstanding:126.02

Cash Conversion Cycle:-49.74

C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00

Quality Score:40.00

Market Metrics (2)

Beta:0.00x

Volatility Category:unknown

DIVISION IV: INVESTMENT ANALYSIS

A. Value Investment Framework

Owner Earnings Analysis (1)

-$104.08M

Damodaran Growth Analysis (2)

Reinvestment Rate:2.9%

Fundamental Growth Rate (g):-0.9%

B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-34.3%

Other Growth Rates (1)

Book Value Growth Rate (Linear):11.4%

C. Company Profile & Context

Corporate Information (6)

Symbol:DAWN

Company Name:DAY ONE BIOPHARMACEUTICALS, INC.

Sector:Healthcare

Industry:Pharmaceuticals

Exchange:NASDAQ

Country:United States

Market Classification (3)

Market Cap Category:N/A

Price Category:medium

Volume Category:N/A

Share Structure (3)

Shares Outstanding:103.21M

Shares Outstanding Basic:103.21M

Shares Outstanding Diluted:103.21M

Data Processing Info (3)

Processing Version:v3.0

Last Updated:2026-06-05 18:35:04 UTC

Data Timestamp:2026-06-03T04:08:29.456785